RxDoctor Payments Data

Aaditya Vora, MD

Clinical Cardiac Electrophysiology · Jacksonville, FLNPI 1083898449

Payments from drug & device makers

$84,700in general payments, 2019–2025

Across 363 payments — averaging $233.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$51K
  • Elutia, Inc.$23K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Boston Scientific$1K
  • Abbott$1K
  • Biosense Webster, Inc.$782
  • plus $4K from 29 others

What the payments were for

  • Speaking & faculty fees$31,95051%
  • Travel & lodging$18,87530%
  • Food & beverage$11,05918%
  • Education$1660%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,700 in reported general payments places this provider in the 70th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$617,929
Medicare patients
2,357
Services billed
5,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban559$589,025
VyndamaxTafamidis12$311,198
MultaqDronedarone Hcl59$75,109
XareltoRivaroxaban70$65,720
EntrestoSacubitril/Valsartan38$37,504
Dofetilide66$11,735
Flecainide Acetate127$5,467
Metoprolol Succinate323$4,860
Dabigatran EtexilateDabigatran Etexilate Mesylate21$3,368
SotalolSotalol Hcl135$2,260
Diltiazem 24hr Er (Cd)Diltiazem Hcl96$2,021
Amiodarone Hcl53$917
Atorvastatin Calcium56$734
Rosuvastatin Calcium26$655
Isosorbide Mononitrate ErIsosorbide Mononitrate17$601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$497$900,223571 claims
Sanofi-aventis U.S. LLCMultaq$20$75,10959 claims
Johnson & JohnsonXarelto$192$65,72070 claims
NovartisEntresto$291$37,50438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →